Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CASI Files for Fourth China Trial of Lead Cancer Drug

publication date: Jun 5, 2015
CASI Pharma, a US-China biopharma, filed for CFDA approval to begin a China Phase II clinical trial of its lead novel drug candidate, ENMD-2076, in patients with fibrolamellar carcinoma (FLC). The trial is an extension of a similar US trial. CASI has already started three other US-China Phase II tests of the drug for various forms of cancer. Headquartered in Maryland with a lab in Beijing, CASI in-licenses products for the China market, but is developing ENMD-2076 globally. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital